Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice

@article{Polin2002PreclinicalEE,
  title={Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice},
  author={Lisa Marie Polin and Kathryn White and Juiwanna Kushner and Jennifer Paluch and Chiab Simpson and S. Y. R. Pugh and Matthew K. Edelstein and Stuart T. Hazeldine and Joseph Fontana and Patricia Lorusso and Jerome P. Horwitz and Thomas H. Corbett},
  journal={Investigational New Drugs},
  year={2002},
  volume={20},
  pages={13-22}
}
XK-469 is advancing to Phase I clinicaltrials. Preclinical studies were carriedout to assist in clinical applications.Dose-schedule route testing: Singledose IV treatment with XK-469 producedlethality (LD20 to LD 100) above 142 mg/kg.Optimum treatment required total dosages of350 to 600 mg/kg. Furthermore, highindividual IV dosages (100 to 142 mg/kg)were poorly tolerated, producingsubstantial weight loss (8 to 18% of bodyweight), poor appearance, and slow recovery(8 to 12 days). A 1-hour… CONTINUE READING